Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2001-05-29
2009-11-24
Belyavskyi, Michail A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07622557
ABSTRACT:
The present invention includes methods of identifying and/or isolating stem cells based on expression of BCRP. The present invention also describes methods of obtaining and/or using cell populations enriched for stem cells. In addition, methods are provided for diagnosing and/or prognosing leukemia, particularly human acute myelogenous leukemia (AML), through assaying for BCRP expression in leukemic cells.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5563247 (1996-10-01), Niman et al.
patent: 5571687 (1996-11-01), Casey et al.
patent: 5994088 (1999-11-01), Mechetner et al.
patent: 6313277 (2001-11-01), Ross et al.
patent: 6485933 (2002-11-01), Bandman et al.
patent: 6528623 (2003-03-01), Godfrey et al.
patent: WO 93/24613 (1993-12-01), None
patent: WO 97/16535 (1997-05-01), None
patent: WO 98/12304 (1998-03-01), None
patent: WO 99/40110 (1998-08-01), None
patent: WO 99/61589 (1999-12-01), None
Scheffer et al, Proc Am Assoc Cancer Res Mar. 2000;41:p. 803.
Kohler et al, Eur J. Immunol 1976;6511-9.
Datasheet for clone 4E3 antibody, DAKO Corp. 2004.
Arcesi et al, Cancer Res. 1993;53:310-7.
Owens et al., J of Immunological methods, 1994, vol. 168, pp. 149-165.
U.S. Appl. No. 60/086,988, filed May 28, 1998, Provisional.
Allen et al., Cancer Res., 59: 4237-41, 1999.
Allikmets et al., Hum. Mol. Genet., 5: 1649-55, 1996.
Bhatia et al., Nat Med.,, 4: 1038-45, 1998.
Bhatia et al., J Exp. Med., 186: 619-624, 1997.
Brangi et al., Cancer Research, 59:5938-5946, 1999.
Bunting et al., Blood, 92(7): 2269-79, 1998.
Chaudhary and Roninson, Cell, 66: 85-94, 1991.
Doyle et al., Proc. Natl. Acad. Sci. USA, 95: 15665-15670,1998.
Galipeau et al., Human Gene Therapy., 8: 1773-83, 1997.
Giles et al., Cancer, 86: 805-813, 1999.
Glimm and Eaves, Blood, 94: 2161-68, 1999.
Goodell et al., J Exp Med., 183: 1797-1806, 1996.
Goodell et al., Nat. Med., 3: 1337-45, 1997.
Gruol and Bourgeois, Biochem. Cell. Biol., 72: 561-71, 1994.
Gussoni et al, Nature, 401: 390-4, 1999.
Hanania et al., Cancer Gene Therapy, 1(1): 21-25, 1994.
Hanania et al., Gene Ther., 2: 279-84, 1995.
Hrycyna et al., Biochemistry, 37: 13660-73, 1998.
Jackson et al., PNAS USA, 96: 14482-86, 1999.
Johnstone et al., Blood, 93: 1075-85, 1999.
Leith et al., Blood, 94: 1086-99, 1999.
Malieparard et al., Cancer Res., 59: 4559-63, 1999.
Michieli et al., Br. J. Haematol, 104: 328-335, 1999.
Miyake et al., Cancer Res., 59: 8-13, 1999.
Nakayama et al., Blood, 92: 4296-4307, 1998.
Osawa et al., Science, 273: 242-45, 1996.
Persons et al., Blood, 90(5):1777-1786, 1997.
Podda et al., PNAS USA, 89: 9676-80, 1992.
Robinson et al., Biochemistry, 36: 11169-78, 1997.
Ross et al., Blood, 96(1):365-368, 2000.
Schinkel et al., PNAS USA, 94: 4028-33, 1997.
.Shimizu et al., Blood, 91: 3688-92, 1998.
Smyth et al., PNAS USA, 95: 7024-29, 1998.
Sorrentino et al., Science, 257: 99-103, 1992.
Sorrentino et al., Blood, 86: 491-501, 1995.
Spencer et al., Blood, 87: 2579-87, 1996.
Tisdale et al., Blood, 92: 1131-41, 1998.
Traycoff et al., Exp. Hemotol., 26: 53-62, 1998.
Zandstra et al., Proc. Natl. Acad. Sci. USA, 94:4698-4703, 1997.
Zanjani et al., Exp. Hematol., 26: 353-60, 1998.
Ziegler et al., Science, 285: 1553-8, 1999.
Bunting K.D., “ABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells”, Stem Cells 2002 20:11-20.
Wall et al., “The BCRP Gene Product Transports the Stem Cell Marker Hoechst 33342 and Function Depends upon the Amount of Protein and an Intact Walker A Motif”, Proceedings of the American Association for Cancer Research Annual, vol. 42 Mar. 2001, p. 281 XP001093958.
Zhou et al., “The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype” Nature Medicine 2001 7(9) : 1028-1034.
Zhou et al., “Expression of the Breast Cancer Resistance Protein (BCRP) in Side Population (SP) Stem Cells, Natural Killer (NK) Lymphocytes, and Erythroid Progenitor Cells”, Blood 2000 96(11) :820a.
Ozvegy-Laeka, et al.; Function-dependent conformational changes of the ABCG2 multi-drug transporter modify its interaction with a monoclonal antibody on the cell surface;J. Biol. Chem.2005; 280(6): 4219-4227.
Diestra J.E., et al.; Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material;J. Pathol.Oct. 2002 198(2):213-219.
Maliepaard, M., et al.; Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues;Cancer Res.Apr. 15, 2001; 61(8):3458-3464.
Scheffer G.L., et al.; Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines;Cancer Res.May 15, 2000; 60(10): 2589-2593.
Schuetz John
Sorrentino Brian
Belyavskyi Michail A
Darby & Darby P.C.
St. Jude Children's Research Hospital
LandOfFree
Antibodies having binding specificity for the extracellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies having binding specificity for the extracellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies having binding specificity for the extracellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101046